Prostate-specific antigen (PSA) cutoff for improves clinical judgment before the decision to repeat prostate biopsy
Keywords:
PSA, repeat TRUS Bx prostateAbstract
The purpose of the study to determine the PSA level of patients who positive repeat transrectal ultrasound biopsy(TRUS Bx) prostate that higher or no higher than the PSA level of patients who negative repeat TRUS Bx prostate. To defined the optimal level of PSA for improve clinical judgment before the decision to repeat prostate biopsy.
We reviewed prospectively gathered data that the PSA level of 37 patients who repeat TRUS Bx performed at our institution for compared the PSA level between positive and negative repeat biopsy groups. If significantly higher of PSA level in positive repeat biopsy group, the cutoff of PSA level were evaluated.
Mean of PSA level of positive and negative repeat Bx group was 11.11 and 7.76 ng/ml, respectively and significantly higher in positive repeat Bx group. Cutoff PSA at 9 ng/ml gave the high sensitivity and positive predictive value to predicted outcome of repeat TRUS Bx prostate and gave the acceptable false positive and false negative rate.
In practice, the cutoff PSA will increase chance to detect early prostate cancer and still give the acceptable unnecessary repeat biopsy.
References
Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. Amulti-institutional update. JAMA 1997; 277(18): 1445-51.
Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E, et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002; 167(4): 1664-69.
Epstein Jl, Walsh PC, Carter HB. Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol 2001; 166(5): 1688-91.
Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol 2001; 166(3): 856-60.
Presti JC, Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: Results of a prospective clinical trial. J Urol 2000; 163(1): 179-80.
Meng MV, Franks JH, Presti JC Jr, Shinohara K. The utility of apical anterior horn biopsies in prostate cancer detection. Urol Oncol 2003; 21(5): 361-5.
Mazal PR, Haitel A, Windischberger C, Djavan B, Sedivy R, Moser E, et al. Spatial distribution of prostate cancers undetected on initial needle biopsies. Eur Urol 2001; 39(6): 662-8.
National Comprehensive, 2004. National Comprehensive Cancer Network, 2004. http://www.nccn.org/professionals/physician_gls/ PDF/prostate_detection.pdf
